This pilot study was designed to demonstrate that (in)GSH results in an increase in the GSH signal in brain, and not to generate a comprehensive pharmacokinetic profile of the increased brain GSH signal
GHK-Cu might be more effective in someone with: Oxidative stress gene variants Poor copper transport capacity Collagen breakdown pathways In my next edition, Ill share how genomics, epigenetics, microbiome, metabolomics, and other advanced testing can guide smarter peptide use
Comprehensive Mechanism Review Pickart et al., BioMed Research International (2015) Pickart, Vasquez-Soltero, and Margolina conducted an integrative review of GHK-Cu research spanning the 1973 isolation of the tripeptide through subsequent decades of mechanistic and clinical work
This discussion compares tripeptides, exemplified by the well-studied GHK, with larger peptides such as the cyclic heptapeptide CyRL-QN15, the human cathelicidin-derived antimicrobial peptide LL-37, and the peptide Andersonin W-1 (AW1), containing 7, 37, and 72 amino acids, respectively [25, 67, 68]
